PHENOM
6.6.2024 13:01:27 CEST | Business Wire | Press release
Phenom today released the third annual European Edition of its eighth annual State of Candidate Experience Benchmarks Report, which analyzes and ranks Fortune 500 companies based on how they are attracting, engaging and converting talent throughout the candidate journey. The European audit report revealed the majority of organisations are failing to leverage data and personalised, contextual information to support candidates throughout their journey to find the right work — for example, 96% did not ask about skills to match candidates with related job openings.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240606262890/en/
Phenom’s third annual European Edition of its eighth annual State of Candidate Experience Benchmarks Report revealed the majority of organisations are failing to leverage data and personalised, contextual information to support candidates throughout their journey to find the right work. For example, 96% did not ask about skills to match candidates with related job openings. The audit report analyzes and ranks Fortune 500 companies based on how they are attracting, engaging and converting talent throughout the candidate journey. (Graphic: Business Wire)
With these opportunities to improve considered, the report also highlights notable year-over-year progress when leveraging AI, automation and talent marketing strategies to enhance experiences for candidates — including a 529% increase in featuring dynamically curated content, including information about the company, open jobs, benefits, culture, employee testimonials and interview tips.
Opportunities to Improve Matching Candidates with the Right Work
- 97% do not have social media content embedded in the job seeker experience
- 96% do not provide job recommendations based on experience level or job titles
- 95% do not have job recommendations based on a created profile
- 89% do not automatically detect the candidate’s geographic location to suggest relevant, nearby jobs
- 20% decrease of having a chatbot on career site
How the European 100 is Building Better Candidate Journeys with AI and Engaging Content
- 123% increase in displaying video content featuring employee testimonials that showcase company culture and reasons to work there
- 87% provide an easy authentication process for returning users
- 79% have content in multiple languages tailored to specific locations
- 32% increase in featuring a job cart or ability to easily favorite jobs
- 10% increase in having a clearly visible and accessible “apply” button
Over the past year, the European labor market has been heavily influenced by supply chain disruptions affecting regional supplies, demographic shifts causing labor shortages, and the prioritisation of DE&I in the workplace — among other things.
Simply publishing a career site is no longer enough; talent acquisition teams, talent marketers, and recruiters must invest in the right AI and personalization technology, content and talent marketing strategies, employer branding and user experience to establish indispensable connections that convert job seekers into applicants.
Recommendations to Improve the Candidate Experience
Phenom’s 2024 European Edition of the State of Candidate Experience report includes prescriptive guidance for organisations seeking to improve how they attract, engage and convert talent with automation and intelligence.
-
Attracting and engaging top talent faster. Candidates continue to search for their next job across many disparate channels. Organisations must adopt a comprehensive talent marketing approach that makes jobs widely accessible. Consistent branding and a clear value proposition should be reflected in every step of the journey.
-
Delivering a one-of-a-kind experience. Candidates are unlikely to apply if it is difficult to find information when researching a potential employer. AI and automation can personalise every touchpoint and streamline the discovery of relevant opportunities.
- Turning passive job seekers into new hires with a seamless process. Candidates no longer complete job applications that are time and labor intensive. Organisations must introduce a fast and frictionless job discovery and application process, spanning no more than 3 minutes for high-volume roles.
“It’s clear the competition for top talent is not won by a standalone career site or chatbot — job seekers are engaging with companies across a multitude of channels,” said John Harrington, Sr. Director, Product Marketing at Phenom. “Savvy organisations are keeping up by leveraging intelligence and automation to deliver personalised candidate experiences across every touchpoint, ultimately improving the way they engage and convert a broader talent pool.”
With Phenom, candidates find and choose the right job faster, employees develop their skills and evolve, recruiters become wildly productive, talent marketers engage with extreme efficiency, talent leaders optimize hiring processes, managers build stronger-performing teams, HR aligns employee development with company goals, and HRIS easily integrates existing HR tech to create a holistic infrastructure.
To read the full 2024 report and European 100 company rankings, get the report here.
Organisations not featured in the report can request their own complimentary candidate experience audit here.
About Phenom
Phenom has a purpose of helping a billion people find the right work. Through AI-powered talent experiences, employers use Phenom to hire employees faster, develop them to their full potential, and retain them longer. The Phenom Intelligent Talent Experience platform seamlessly connects candidates, employees, recruiters, talent marketers, talent leaders, hiring managers, HR and HRIS — empowering diverse and global enterprises with innovative products including Phenom X+ Generative AI, Career Site, Chatbot, CMS, Talent CRM, One-Way Interviews, Automated Interview Scheduling, Interview Intelligence, Talent Experience Engine, Campaigns, University Recruiting, Contingent Talent Hiring, Talent Marketplace, Workforce Intelligence, Career Pathing, Gigs, Mentoring, and Referrals.
Phenom has earned accolades including: Inc. 5000’s fastest-growing companies (4 consecutive years), Deloitte Technology's Fast 500 (4 consecutive years), five Brandon Hall ‘Excellence in Technology’ awards including Gold for ‘Best Advance in AI for Business Impact,’ Business Intelligence Group's Artificial Intelligence Excellence Awards (3 consecutive years), and a regional Timmy Award for launching and optimizing HelpOneBillion.com (2020).
Headquartered in Greater Philadelphia, Phenom also has offices in India, Israel, the Netherlands, Germany and the United Kingdom.
For more information, please visit www.phenom.com. Connect with Phenom on LinkedIn, X, Facebook, YouTube and Instagram.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240606262890/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
First Randomized Controlled Trial Shows Promise of a Ketogenic Diet in Psychotic Disorders8.7.2026 15:00:00 CEST | Press release
Trial reports correlations between ketone levels and cognitive and psychiatric symptoms in individuals with schizophrenia-spectrum and bipolar-1 disorders Published today in Schizophrenia Bulletin, a first-of-its-kind randomized controlled trial (RCT) from researchers at the University of California, San Francisco (UCSF), and funded in part by the National Institute of Mental Health (NIMH), adds to growing literature on the potential benefit of a ketogenic diet for treating psychotic disorders. The study, which enrolled participants with schizophrenia-spectrum or bipolar-1 disorders, demonstrated rapid metabolic improvements with a ketogenic diet compared to diet-as-usual during an initial one-month RCT open-label phase. Furthermore, those who continued with the optional four-month single-arm ketogenic diet extension saw meaningful gains across metabolic, psychiatric, and cognitive measures. This press release features multimedia. View the full release here: https://www.businesswire.co
Teamily AI Publicly Launches Human+AI Social Platform to Make Building and Growing a Company Easy for Every Team8.7.2026 15:00:00 CEST | Press release
Teamily AI (https://Teamily.ai), together with its Agentic AI Infra platform TensorOpera AI (https://TensorOpera.ai), today announced the public launch of its Human+AI social platform, a product stack that has already served more than 5 million users around the world. Starting today in Palo Alto and rolling out simultaneously across dozens of countries, this first public launch opens the full stack to everyone with a single mission: to make building and growing a company easy for every person and every team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708584390/en/ "This is the moment we open our doors to the world," said co-founders Dr. Aiden Chaoyang He and Professor Salman Avestimehr. "We want every person and every team to be able to move from idea to product, from product to market, and from market to growth and investment, with an AI-native team by their side." At its core, Teamily AI enables humans and AI agents
Leo Cancer Care Raises $65M Series D to Scale Its Integrated Upright Cancer Care Platform8.7.2026 14:30:00 CEST | Press release
Oversubscribed round follows the world-first compact upright proton treatment at Stanford Medicine — funding a single upright platform that will span imaging and treatment across multiple radiation modalities. Leo Cancer Care, the medical technology company working to reinvent how patients are imaged and treated by designing systems around the body’s natural upright position, today announced the close of an oversubscribed $65 million Series D financing. The round was led by Silicon Valley’s Yu Galaxy and welcomes new investors including Eventide Asset Management, alongside continued support from the company’s existing investors. Leading cancer institutions are already adopting the upright approach. Stanford Medicine delivered the world’s first compact upright proton therapy treatment on 4 June 2026. Dana-Farber Cancer Institute and McLaren Health Care are among the institutions bringing the upright platform into their programmes — adoption that spans world-leading academic centers and
LUMI AI Factory Selects IQM to Deploy Advanced Quantum Computer, Accelerating Hybrid HPC and AI Development8.7.2026 14:00:00 CEST | Press release
The Halocene H4 quantum computer, named LUMI-IQ, will be delivered and installed in 2027 The system will be hosted at CSC – IT Center for Science in Finland and integrated into the LUMI AI Factory The system will provide researchers, industry innovators, and developers across Europe with a unique, advanced experimental platform where quantum computing and artificial intelligence converge The LUMI AI Factory, led by CSC – IT Center for Science, has selected IQM Quantum Computers (Nasdaq: IQMX) to deliver IQM Halocene H4, an advanced quantum computer aimed at accelerating hybrid high-performance computing, artificial intelligence, and quantum computing capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708006791/en/ LUMI AI Factory selects IQM to deploy advanced quantum computer, accelerating hybrid HPC and AI development IQM Halocene H4 is the first and most advanced on-premises superconducting quantum computer o
Merck Announces FDA Breakthrough Therapy Designation for Enpatoran in Lupus Patients With Active Skin Manifestations8.7.2026 14:00:00 CEST | Press release
Enpatoran could address a significant unmet need in lupus, specifically targeting cutaneous manifestations of the disease, which currently have no approved therapiesFDA's decision was supported by Phase 2 WILLOW study results, which demonstrated meaningful symptoms improvement, particularly among patients with active cutaneous manifestationsEnpatoran's potential to go beyond current treatment standards in lupus prompted FDA´s breakthrough designation, which is designed to expedite drug development and reviewNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to enpatoran for the treatment of lupus with active cutaneous manifestations. Enpatoran is an oral selective toll-like receptor (TLR) 7/8 inhibitor, designed to modulate pathways central to lupus-related inflammation. “For the 85% of lupus patients whose disease includes skin manif
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom